Bristol-Myers Squibb Company (BRM BE) stock market data APIs
€51.8066
0.02(0%)
as of March 18, 2026
Try our APIs with
free plan!
Bristol-Myers Squibb Company Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for BRM.BE.
Prev. Close
51.8066
Open
51.8277
High
52.0729
Low
51.4596
52 wk Range
36.2474-53.6195
Market Cap
110 771 M
Dividends (Yield)
0.0157
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bristol-Myers Squibb Company data using free add-ons & libraries
Get Bristol-Myers Squibb Company Fundamental Data
Bristol-Myers Squibb Company Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bristol-Myers Squibb Company News
New
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX0...
ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Transaction enables exposure to both oral drug delivery program & medical device businesses Oramed Pharmaceuticals (NASDAQ:ORMP) recently...
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Sto...
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival ("PFS") and overall survival ("OS") in an interim analysis of a Phase 3 trial (NCT06382142) conducted in ...
Get Bristol-Myers Squibb Company fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
